JP7370958B2 - 血液悪性腫瘍の治療 - Google Patents

血液悪性腫瘍の治療 Download PDF

Info

Publication number
JP7370958B2
JP7370958B2 JP2020505341A JP2020505341A JP7370958B2 JP 7370958 B2 JP7370958 B2 JP 7370958B2 JP 2020505341 A JP2020505341 A JP 2020505341A JP 2020505341 A JP2020505341 A JP 2020505341A JP 7370958 B2 JP7370958 B2 JP 7370958B2
Authority
JP
Japan
Prior art keywords
cells
monoclonal antibody
labeled
pharmaceutical composition
actinium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020505341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529416A (ja
Inventor
サンデシュ セス
ケイシャ トーマス
Original Assignee
アクティニウム ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクティニウム ファーマシューティカルズ インコーポレイテッド filed Critical アクティニウム ファーマシューティカルズ インコーポレイテッド
Publication of JP2020529416A publication Critical patent/JP2020529416A/ja
Priority to JP2023179304A priority Critical patent/JP7728310B2/ja
Application granted granted Critical
Publication of JP7370958B2 publication Critical patent/JP7370958B2/ja
Priority to JP2025134190A priority patent/JP2025183210A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020505341A 2017-07-31 2018-07-31 血液悪性腫瘍の治療 Active JP7370958B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023179304A JP7728310B2 (ja) 2017-07-31 2023-10-18 血液悪性腫瘍の治療
JP2025134190A JP2025183210A (ja) 2017-07-31 2025-08-12 血液悪性腫瘍の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539114P 2017-07-31 2017-07-31
US62/539,114 2017-07-31
PCT/US2018/044531 WO2019027973A1 (en) 2017-07-31 2018-07-31 TREATMENTS FOR HEMATOLOGICAL MALIGNANCY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023179304A Division JP7728310B2 (ja) 2017-07-31 2023-10-18 血液悪性腫瘍の治療

Publications (2)

Publication Number Publication Date
JP2020529416A JP2020529416A (ja) 2020-10-08
JP7370958B2 true JP7370958B2 (ja) 2023-10-30

Family

ID=65233069

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020505341A Active JP7370958B2 (ja) 2017-07-31 2018-07-31 血液悪性腫瘍の治療
JP2023179304A Active JP7728310B2 (ja) 2017-07-31 2023-10-18 血液悪性腫瘍の治療
JP2025134190A Pending JP2025183210A (ja) 2017-07-31 2025-08-12 血液悪性腫瘍の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023179304A Active JP7728310B2 (ja) 2017-07-31 2023-10-18 血液悪性腫瘍の治療
JP2025134190A Pending JP2025183210A (ja) 2017-07-31 2025-08-12 血液悪性腫瘍の治療

Country Status (7)

Country Link
US (1) US20200121815A1 (https=)
EP (2) EP3661557B1 (https=)
JP (3) JP7370958B2 (https=)
CN (1) CN111050796A (https=)
ES (1) ES3049118T3 (https=)
PL (1) PL3661557T3 (https=)
WO (1) WO2019027973A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083192B2 (en) 2017-12-04 2024-09-10 Actinium Pharmaceuticals, Inc. Methods for treatment of patients with myelodysplastic syndromes
WO2020132672A1 (en) 2018-12-21 2020-06-25 Actinium Pharmaceuticals, Inc. Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
US20220202967A1 (en) * 2019-04-25 2022-06-30 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
CN114258401B (zh) * 2019-07-16 2025-08-12 Inserm(法国国家健康医学研究院) 对cd38具有特异性的抗体及其用途
WO2021134045A1 (en) * 2019-12-26 2021-07-01 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent
CA3196402A1 (en) * 2020-10-22 2022-04-28 Dale L. Ludwig Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
WO2022216965A1 (en) * 2021-04-07 2022-10-13 Actinium Pharmaceuticals, Inc. Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells
WO2023045859A1 (zh) * 2021-09-23 2023-03-30 非同（成都）生物科技有限公司 Cd38单克隆抗体及其应用
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体
WO2024131849A1 (zh) * 2022-12-21 2024-06-27 非同（成都）生物科技有限公司 Cd38单克隆抗体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006513203A (ja) 2002-12-31 2006-04-20 イミューノメディクス、インコーポレイテッド 非コンジュゲートおよびコンジュゲート抗体、抗体の組合せおよび融合タンパク質を用いるｂ細胞悪性腫瘍および自己免疫疾患の免疫療法
US20120076727A1 (en) 2007-01-11 2012-03-29 Immunomedics, Inc. In Vivo Copper-Free Click Chemistry for Delivery of Therapeutic and/or Diagnostic Agents
JP2013500258A (ja) 2009-07-22 2013-01-07 アクティニウム ファーマシューティカルズ インコーポレイテッド 放射性免疫複合体を生成するための方法
US20150283275A1 (en) 2012-11-05 2015-10-08 Morphosys Ag Radiolabelled Antibody And Uses Thereof
JP2016513203A (ja) 2013-02-06 2016-05-12 シーメンス アクチエンゲゼルシヤフトＳｉｅｍｅｎｓ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ねじれリブを有するねじれガスタービンエンジンエアフォイルのための鋳造コア

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
CA2411102A1 (en) * 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
NZ530212A (en) 2001-06-13 2006-09-29 Genmab As An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DK2580243T3 (da) * 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
SI2621531T1 (sl) 2010-09-27 2017-06-30 Morphosys Ag Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl
BR112015030457A2 (pt) * 2013-06-07 2017-08-22 Nordic Nanovector As Método para regular positivamente a expressão de antígeno
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2020132672A1 (en) * 2018-12-21 2020-06-25 Actinium Pharmaceuticals, Inc. Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006513203A (ja) 2002-12-31 2006-04-20 イミューノメディクス、インコーポレイテッド 非コンジュゲートおよびコンジュゲート抗体、抗体の組合せおよび融合タンパク質を用いるｂ細胞悪性腫瘍および自己免疫疾患の免疫療法
US20120076727A1 (en) 2007-01-11 2012-03-29 Immunomedics, Inc. In Vivo Copper-Free Click Chemistry for Delivery of Therapeutic and/or Diagnostic Agents
JP2013500258A (ja) 2009-07-22 2013-01-07 アクティニウム ファーマシューティカルズ インコーポレイテッド 放射性免疫複合体を生成するための方法
US20150283275A1 (en) 2012-11-05 2015-10-08 Morphosys Ag Radiolabelled Antibody And Uses Thereof
JP2016513203A (ja) 2013-02-06 2016-05-12 シーメンス アクチエンゲゼルシヤフトＳｉｅｍｅｎｓ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ねじれリブを有するねじれガスタービンエンジンエアフォイルのための鋳造コア

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Research, 2013, Vol.74, No.4, pp.1179-1189，DOI: 10.1158/0008-5472.can-13-1589
N. Engl. J. Med., 2015, Vol.373, pp.1207-1219，DOI: 10.1056/NEJMoa1506348
Oncotarget, 2014, Vol.6, No.7, pp.4692-4703

Also Published As

Publication number Publication date
EP3661557C0 (en) 2025-09-03
CA3071609A1 (en) 2019-02-07
EP3661557B1 (en) 2025-09-03
EP3661557A4 (en) 2021-04-14
EP4592320A2 (en) 2025-07-30
JP2020529416A (ja) 2020-10-08
ES3049118T3 (en) 2025-12-15
US20200121815A1 (en) 2020-04-23
CN111050796A (zh) 2020-04-21
JP2025183210A (ja) 2025-12-16
JP2024016055A (ja) 2024-02-06
PL3661557T3 (pl) 2025-11-03
EP3661557A1 (en) 2020-06-10
JP7728310B2 (ja) 2025-08-22
EP4592320A3 (en) 2025-09-24
WO2019027973A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
JP7728310B2 (ja) 血液悪性腫瘍の治療
KR101155957B1 (ko) Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
CZ2005487A3 (cs) Imunoterapie B-lymfocytárních malignit a autoimunitních onemocnění za použití nekonjugovaných a konjugovaných protilátek, kombinací protilátek a fúzních proteinů
CN102209556A (zh) 改良的抗cd19抗体
WO2019094626A1 (en) Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies
JP2024100847A (ja) 血液悪性腫瘍の治療のための併用免疫療法及び化学療法
US20260053963A1 (en) Radioconjugates targeting cd33 in the treatment of breast cancer
JP2023546679A (ja) がん治療における放射免疫療法とｃｄ４７遮断の併用
US12539340B2 (en) Radioconjugates targeting CD33 in the treatment of cancers
EP4380632A1 (en) Radioconjugates targeting cd33 in the treatment of cancers
CA3071609C (en) Treatments for a hematological malignancy
US20230302168A1 (en) Dr5 radioimmunotherapy in the treatment of solid cancers
JP2024528081A (ja) 癌の治療における放射免疫療法及びｃｄ４７遮断薬の組み合わせ
EP3706785B1 (en) Combination of radionuclide-conjugated antibodies for treatment of a hematological malignancies
JP2023550462A (ja) 固形がんの治療のためのｈｅｒ３放射免疫治療薬
HK40027727A (en) Treatments for a hematological malignancy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230703

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230921

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231018

R150 Certificate of patent or registration of utility model

Ref document number: 7370958

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150